6533b870fe1ef96bd12cfd47

RESEARCH PRODUCT

Neurogranin as a Novel Biomarker in Alzheimer's Disease

Tommaso PiccoliCaterina Maria GambinoMarcello CiaccioGiulia BivonaSalvatore MilanoLuisa AgnelloAnna Maria CiaccioVincenzo La BellaBruna Lo Sasso

subject

MaleOncologymedicine.medical_specialtyClinical BiochemistryDiseaseSensitivity and SpecificityCerebrospinal fluidAlzheimer DiseaseInternal medicineHumansMedicineNeurograninCognitive declineAgedRetrospective StudiesReceiver operating characteristicbusiness.industryBiochemistry (medical)Area under the curveMiddle Agedmedicine.diseaseCSF biomarker neurogranin synapsis synaptic loss α-synucleinalpha-SynucleinBiomarker (medicine)FemaleNeurograninAlzheimer's diseasebusinessBiomarkers

description

Abstract Background In this study, we investigated the possible role of 2 novel biomarkers of synaptic damage, namely, neurogranin and α-synuclein, in Alzheimer disease (AD). Methods The study was performed in a cohort consisting of patients with AD and those without AD, including individuals with other neurological diseases. Cerebrospinal fluid (CSF) neurogranin and α-synuclein levels were measured by sensitive enzyme-linked immunosorbent assays (ELISAs). Results We found significantly increased levels of CSF neurogranin and α-synuclein in patients with AD than those without AD. Neurogranin was correlated with total tau (tTau) and phosphorylated tau (pTau), as well as with cognitive decline, in patients with AD. Receiver operating characteristic (ROC) curve analysis showed good diagnostic accuracy of neurogranin for AD at a cutoff point of 306 pg per mL with an area under the curve (AUC) of 0.872 and sensitivity and specificity of 84.2% and 78%, respectively. Conclusions Our findings support the use of CSF neurogranin as a biomarker of synapsis damage in patients with AD.

yearjournalcountryeditionlanguage
2020-09-15
10.1093/labmed/lmaa062http://hdl.handle.net/10447/483360